1Triphenylmethyl-2-phthalimidoimidazole | 185563-92-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 1Triphenylmethyl-2-phthalimidoimidazole
• 英文别名: 2-[1-(Triphenylmethyl)-1H-imidazol-2-yl]-1H-isoindole-1,3(2H)-dione；2-(1-tritylimidazol-2-yl)isoindole-1,3-dione
• CAS: 185563-92-2
• 化学式: C₃₀H₂₁N₃O₂
• 分子量: 455.516
• InChiKey: NZWBLZZDAZWKAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.03
• 拓扑面积：
  55.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1Triphenylmethyl-2-phthalimidoimidazole 在 lithium hydroxide 、 三乙酰氧基硼氢化钠 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 、 肼 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 49.5h， 生成 (S)-2-(3,5-Dichloro-biphenyl-4-sulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid tert-butyl ester
  参考文献：
  名称：

  Isoxazolines as Potent Antagonists of the Integrin α_vβ₃

  摘要：

  Starting with lead compound 2, we sought to increase the selectivity for alpha(v)beta(3)-mediated cell adhesion by examining the effects of structural changes in both the guanidine mimetic and the substituent alpha to the carboxylate. To prepare some of the desired aminoimidazoles, a novel reductive amination utilizing a trityl-protected aminoimidazole was developed. It was found that guanidine mimetics with a wide range of pK(a)'s were potent antagonists of alpha(v)beta(3). In general, it appeared that an acylated 2-aminoimidazole guanidine mimetic imparted excellent selectivity for alpha(v)beta(3)-mediated adhesion versus alpha(IIb)beta(3)-mediated platelet aggregation, with selectivity of approximately 3 orders of magnitude observed for compounds 3g and 3h. It was also found in this series that the alpha-substituent was required for potent activity and that 2,6-disubstituted arylsulfonamides were optimal. In addition, the selective alpha(v)beta(3) antagonist 3h was found to be a potent inhibitor of alpha(v)beta(3)-mediated cell migration.

  DOI：

  10.1021/jm9900321
• 作为产物：
  描述：

  三苯基氯甲烷 在 三乙胺 作用下， 以 正己烷 、 二氯甲烷 为溶剂， 以70%的产率得到1Triphenylmethyl-2-phthalimidoimidazole
  参考文献：
  名称：

  Integrin receptor antagonists

  摘要：

  这项发明涉及新颖的杂环化合物，包括3-\x9b1-\x9b3-(咪唑啉-2-基氨基)丙基!吲唑-5-基甲酰胺!-2-(苄氧羰基氨基)丙酸，这些化合物可作为α.sub.v β.sub.3整合素及相关细胞表面粘附蛋白受体的拮抗剂，用于含有这些化合物的药物组合物，制备这些化合物的方法，以及使用这些化合物单独或与其他治疗剂联合用于抑制细胞黏附、治疗血管生成障碍、炎症、骨质疏松、癌症转移、糖尿病性视网膜病变、血栓形成、再狭窄、黄斑变性以及其他由细胞黏附和/或细胞迁移和/或血管生成介导的疾病的方法。

  公开号：

  US05760028A1

文献信息

• US5760028A
  申请人：——

  公开号：US5760028A

  公开（公告）日：1998-06-02
• Integrin receptor antagonists
  申请人：The DuPont Merck Pharmaceutical Company

  公开号：US05760028A1

  公开（公告）日：1998-06-02

  This invention relates to novel heterocycles including 3-\x9b1-\x9b3-(imidazolin-2-ylamino)propyl!indazol-5-ylcarbonylamino!-2-(benzylo xycarbonylamino)propionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

  这项发明涉及新颖的杂环化合物，包括3-\x9b1-\x9b3-(咪唑啉-2-基氨基)丙基!吲唑-5-基甲酰胺!-2-(苄氧羰基氨基)丙酸，这些化合物可作为α.sub.v β.sub.3整合素及相关细胞表面粘附蛋白受体的拮抗剂，用于含有这些化合物的药物组合物，制备这些化合物的方法，以及使用这些化合物单独或与其他治疗剂联合用于抑制细胞黏附、治疗血管生成障碍、炎症、骨质疏松、癌症转移、糖尿病性视网膜病变、血栓形成、再狭窄、黄斑变性以及其他由细胞黏附和/或细胞迁移和/或血管生成介导的疾病的方法。
• Isoxazolines as Potent Antagonists of the Integrin α_vβ₃
  作者：William J. Pitts、John Wityak、Joanne M. Smallheer、A. Ewa Tobin、James W. Jetter、Jennifer S. Buynitsky、Patricia P. Harlow、Kimberly A. Solomon、Martha H. Corjay、Shaker A. Mousa、Ruth R. Wexler、Prabhakar K. Jadhav

  DOI：10.1021/jm9900321

  日期：2000.1.1

  Starting with lead compound 2, we sought to increase the selectivity for alpha(v)beta(3)-mediated cell adhesion by examining the effects of structural changes in both the guanidine mimetic and the substituent alpha to the carboxylate. To prepare some of the desired aminoimidazoles, a novel reductive amination utilizing a trityl-protected aminoimidazole was developed. It was found that guanidine mimetics with a wide range of pK(a)'s were potent antagonists of alpha(v)beta(3). In general, it appeared that an acylated 2-aminoimidazole guanidine mimetic imparted excellent selectivity for alpha(v)beta(3)-mediated adhesion versus alpha(IIb)beta(3)-mediated platelet aggregation, with selectivity of approximately 3 orders of magnitude observed for compounds 3g and 3h. It was also found in this series that the alpha-substituent was required for potent activity and that 2,6-disubstituted arylsulfonamides were optimal. In addition, the selective alpha(v)beta(3) antagonist 3h was found to be a potent inhibitor of alpha(v)beta(3)-mediated cell migration.